Document is current

Article History

Received: 7 December 2024

Accepted: 7 May 2025

First Online: 30 May 2025

Declarations

:

: Ethical approval for this study (approval number 100/2024) has been obtained from the institutional review board (IRB) at Trier University (‘Ethikkommission der Universität Trier’). All study procedures will be conducted in accordance with the ethical standards and relevant national guidelines for research involving human participants. Participants will be informed about the purpose, procedures, potential risks, and benefits of the study, and will be required to provide informed consent before enrolment.Recordings of group interviews will be conducted and utilised only if informed consent is provided by all participants involved. This ensures that personal data is handled with respect to individual privacy and consent preferences.Participants will be asked to provide consent that data can be used for additional research questions, e.g. bias in AI-enhanced exercises or other (‘opt in’) and that they can be recontacted for further data collection, e.g. follow-up analyses (‘opt in’).

: Not applicable.

: G.M. received funding from the Stanley Thomas Johnson Stiftung & Gottfried und Julia Bangerter-Rhyner-Stiftung under projects no. PC 28/17 and PC 05/18, from the Swiss Cancer League under project no. KLS-4304-08-2017, and in the context of a Horizon Europe project from the Swiss State Secretariat for Education, Research and lnnovation (SERI) under contract number 22.00094. Further, G.M. received funding from Wings Health Inc. in the context of a proof-of-concept study. G.M. received funding from the Swiss Heart Foundation under project no. FF21101, from the Research Foundation of the International Psychoanalytic University (IPU) Berlin under projects no. 5087 and 5217, from the Swiss National Science Foundation (SNSF) under project no. 100014_135328, from the German Federal Ministry of Education and Research under budget item 68606, and from the Hasler Foundation under project no. 23004. G.M. is co-founder and holds stock in Therayou AG, which is active in the field of digital and blended mental healthcare. G.M. receives royalties from publishing companies as author, including a book published by Springer, and an honorarium from Lundbeck for speaking at a symposium. Furthermore, G.M. is compensated for providing psychotherapy to patients, acting as a supervisor, serving as a self-experience facilitator (‘Selbsterfahrungsleiter’), and for postgraduate training of psychotherapists and supervisors. M.T., S.K., E.B., T.S., and M.S. have nothing to report.